Endonovo Therapeutics Highlights Feasibility Study Results of Its Electroceutical Therapy in Reducing Proteinuria in Chronic Kidney Disease Patients
GlobeNewswireMay 1, 2018
Company to Conduct Larger Clinical Study to Evaluate Its Electroceutical™ Therapy in Chronic Kidney Disease
LOS ANGELES, CA, May 01, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapies, today announced that it is targeting the treatment of chronic kidney disease (CKD) using its non-invasive Electroceutical™ Therapy and is currently planning a follow-up clinical study to evaluate its Electroceutical™ Therapy for reducing Proteinuria in CKD patients. Additionally, the Company highlighted positive results from an early feasibility study of its Electroceutical™ Therapy in reducing Proteinuria in 4 patients with CKD. The abstract of the early feasibility study was published in the American Journal of Kidney Diseases and has been posted by the Company on the Presentationssection of its Investor Relations website.
The feasibility study investigated the effectiveness of PEMF during a 2-week trial on reducing Proteinuria (P) in subjects with CKD, evaluating for synergy between Pulsed Electromagnetic Field Therapy (PEMF) and angiotensin receptor blockers (ARBs). Four volunteers with progressive poteinuric nephropathies applied PEMF to their lower-thoracic spine, allowing electromagnetic energy to pulse over both kidneys for 30 min, 3 times a day for 2 weeks. All medications were continued without change, including previously prescribed ARB’s. Urinary spot collections were analyzed for protein to creatinine ratio’s, expressed in grams per day.
During a two-week observational trial, the application of PEMF demonstrated reductions in protein to creatinine ratios expressed on urinary spot collections. Students paired t- test demonstrated in the four subjects, p = 0.06. There were no significant changes in the glomerular filtration rate (MDRD) or mean arterial pressures. No adverse events were reported. The reduction in proteinuria over 2 weeks was arithmetically, but not statistically significant due to small population size. This reduction in proteinuria warrants further study to determine long term effectiveness and possible synergy with RAS blockade.
